Sensex
74,649.84 profit arw 382.50 (0.52%)
Nifty
23,483.55 profit arw 100.95 (0.43%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 02-Jun-2026
Corporate News
02-Jun-2026     18:07

Concord Biotech receives USFDA approval for Mycophenolate Mofetil for Oral Suspension USP

Concord Biotech has received approval from the U.S. Food and Drug Administration (USFDA) for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogeneic kidney, heart or liver transplants, in combination with other immunosuppressants.

INDIAN INDICES

Sensex

74,649.84 382.50 (0.52%)

Nifty

23,483.55 100.95 (0.43%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

26,038.33 640.14(2.52%)